Orcosa Announces Results from Leading Phase 1/2 Clinical Trial Utilizing ORAVEXX™ to be Presented at American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting

Ewing, NJ – March 17, 2022 – Orcosa Inc. (“Orcosa” or the “Company”), a life sciences company modernizing the way medicines are taken through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – announced that the positive results in NYU Langone Health’s (“NYU Langone”) multicenter Phase 1/2 clinical trial utilizing Orcosa’s lead product candidate, ORAVEXX™ (cannabidiol, CBD) will be presented by Principal Investigator, Michael J. Alaia, MD, at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting on March 25. 

The trial, which was conducted jointly at NYU Langone and Baptist Health/Jacksonville Orthopaedic Institute and led by Principal Investigator Michael J. Alaia, M.D. of NYU Langone, sought to evaluate safety and impact on post-operative pain, patient satisfaction and opioid consumption following arthroscopic rotator cuff repair in 99 patients.

About ORAVEXX™ 

ORAVEXX™ is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and has the potential to provide a safe, alternative treatment option to opioids and NSAIDs. Historically, research on the effects of CBD has been limited by a variety of issues including inaccurate dosing, low bioavailability, difficult administration, and a lack of GMP-manufactured products with matching placebos with which to conduct clinical research. ORAVEXX™ is being developed to address these issues. 

About Orcosa Inc.

Orcosa Inc. is a life sciences company modernizing the way medicines are taken and improving patient outcomes through its proprietary therapeutic delivery technology, the Rapid Infusion Technology (RITe™) Platform. Orcosa is the inventor, developer and exclusive owner of the RITe™ Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. Orcosa’s lead program, ORAVEXX™, is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and has the potential to provide a safe, alternative treatment option to opioids and NSAIDs. The company is currently supporting FDA-authorized clinical trials at leading American research institutions to evaluate the safety and effectiveness of ORAVEXX™ for pain management. For more information on Orcosa, please visit https://www.orcosa.com/.

Forward-Looking Statements

Certain statements made herein constitute “forward-looking statements”. These forward-looking statements include, but are not limited to, the development of ORAVEXX™ and the RITe™ Platform.  These statements are based on the current expectations of Orcosa and are not predictions of actual performance. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Orcosa to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Media Contact:

Sard Verbinnen & Co.
Devin Broda
dbroda@sardverb.com
212-687-8080

Investor Contact:

IR@orcosa.com

Share: